0000000000164688

AUTHOR

Andres Jan Schrader

showing 2 related works from this author

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

2012

Abstract Aim of the study Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results pRCC ( n  = 565) and cRCC ( n  = 4376) patients were comparable with re…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologyYoung AdultInternal medicineGermanyCarcinomaMedicineHumansSurvival rateCarcinoma Renal CellAgedRetrospective StudiesAged 80 and overPapillary renal cell carcinomasbusiness.industryIncidenceMiddle Agedmedicine.diseasePrognosisNephrectomyKidney NeoplasmsSurvival RateClear cell renal cell carcinomaOncologyClear cell carcinomaFemalebusinessKidney cancerClear cellEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study

2021

Abstract Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 we…

Oncologymedicine.medical_specialtyUrologyProgrammed Cell Death 1 Receptor030232 urology & nephrology610DiseaseB7-H1 Antigen03 medical and health sciences0302 clinical medicineRenal cell carcinomaInternal medicinePD-L1Biomarkers TumormedicineHumansMedical historyCarcinoma Renal CellPapillary renal cell carcinomasbiologybusiness.industryPrognosismedicine.diseaseKidney NeoplasmsOncology030220 oncology & carcinogenesisCohortbiology.proteinImmunohistochemistrySample collectionbusinessClinical Genitourinary Cancer
researchProduct